Navigation Links
Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024
Date:1/6/2017

LONDON, Jan. 5, 2017 /PRNewswire/ -- The global doxorubicin market was valued at USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

Leukemia- 60,140

Breast cancer - 2,46,660

Endometrial cancer- 60,050

Gastric cancer-26,370

Liver cancer - 39,230

Kidney Cancer- 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Further Key Findings from the Study Suggest:

In 2015, breast cancer is the largest application of doxorubicin market, having a share of around 21.1%. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.

Liver cancer segment is the fastest growing application in this sector. The growing demand for the drug in combination and mono chemotherapies to treat liver cancer over other anticancer drugs is one of the crucial factors that is expected to boost the industry growth.

In 2015, North America held majority of market share of over 48.8% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.

Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Some of the key market players are Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Cipla, Inc., Cadila Pharmaceuticals, and SRS Pharmaceuticals Pvt. Ltd.

Download the full report: https://www.reportbuyer.com/product/4523053/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/doxorubicin-market-by-application-ovarian-multiple-myeloma-kaposi-sarcoma-leukemia-bone-sarcoma-breast-endometrial-gastric-liver-kidney-other-cancers-and-segment-forecasts-2013---2024-300386852.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas
2. Doxorubicin Market Size is Expected to Reach $1.38 Billion by 2024: Grand View Research, Inc.
3. Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
4. CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposis Sarcoma
5. CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting
6. CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
7. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewings Sarcoma
8. CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma
9. CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials
10. CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting
11. CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Gemcitabine in Patients with Metastatic Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... 2018 , ... Cannabidiol, or CBD, has grabbed national headlines in recent months ... precisely why National Day Calendar collaborated with cbdMD to create a holiday in support ... of National CBD Day after weeks of tireless planning in an effort to bring ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... Doctor Snehal ... opportunity to restore their smiles. From now until September 30th, applicants who are in ... for Lorton Springfield Dental Implant & Oral Surgery's Project Smile Program. , "Our local ...
(Date:8/7/2018)... ... , ... Commissioner Gottlieb’s FDA:, Analysis of First Year and a Look Ahead, ... http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes at the FDA have come ... gotten hurt. , And Gottlieb is just getting started. , Mark the calendar for ...
Breaking Medicine Technology:
(Date:8/9/2018)... N.C. and SEATTLE (PRWEB) , ... August 09, 2018 , ... ... of US cases reported per year skyrocketing to an estimated 329,000 – a 25-fold ... Diagnostics Health Trends™ , Lyme disease can be found all 50 states and the ...
(Date:8/9/2018)... , ... August 09, 2018 , ... ... been engaged as an Operating Partner and will have an exclusive relationship with ... role in the firm’s strategic planning, human capital sourcing, and deal origination, evaluation ...
(Date:8/7/2018)... RAPIDS, Mich. (PRWEB) , ... August 07, 2018 , ... ... has partnered with Blue Sky Vision. Michael Sussex, OD, founded the practice in Coldwater, ... Dr. Sussex practices with Matt Austin, OD, to offer comprehensive eye health services for ...
(Date:8/3/2018)... ... 2018 , ... Firstaid4sport have been successfully selling Mueller Sports ... business in the 1990's and his son in law, Michael Davison has now ... the UK of sports medicine products, supplying professional and amateur sports teams and ...
(Date:8/3/2018)... ... 03, 2018 , ... Lucyd Pte Ltd, the developer of ... of its online store. The Lucyd eShop will feature the latest technologies and ... , The eShop will have a number of unique benefits over other ...
Breaking Medicine News(10 mins):